11:44 AM EST - Oncolytics Biotech Inc. : Today announced preclinical data demonstrating the synergistic immunotherapeutic effects of pelareorep combined with radiotherapy in a murine cancer model. The data were featured in a poster presentation at The International Conference on Immunotherapy Radiotherapy Combinations, which took place in Paris. Oncolytics Biotech Inc.
shares T.ONC are trading up $0.05 at $2.73.
